Dennis N. Berman - 21 Jan 2025 Form 4/A - Amendment Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role
Director
Signature
/s/ Dennis Berman
Issuer symbol
IKT
Transactions as of
21 Jan 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
19 Feb 2025, 20:06:52 UTC
Date Of Original Report
22 Jan 2025
Previous filing
07 Jan 2025
Next filing
19 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKT Stock Option (Right to Buy) Award $0 +21,854 $0.000000 21,854 21 Jan 2025 Common Stock 21,854 $1.26 Direct F1, F2, F3, F4
transaction IKT Stock Option (Right to Buy) Award $0 +3,780 $0.000000 3,780 21 Jan 2025 Common Stock 3,780 $1.26 Direct F1, F2, F3, F4
transaction IKT Stock Option (Right to Buy) Award $0 +6,667 $0.000000 6,667 21 Jan 2025 Common Stock 6,667 $1.26 Direct F1, F2, F3, F4
transaction IKT Stock Option (Right to Buy) Award $0 +6,667 $0.000000 6,667 21 Jan 2025 Common Stock 6,667 $1.26 Direct F1, F3, F4
transaction IKT Stock Option (Right to Buy) Award $0 +30,000 $0.000000 30,000 21 Jan 2025 Common Stock 30,000 $1.26 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person's original Form 4, which was filed with the Securities and Exchange Commission on January 22, 2025 inadvertently reported Molino Ventures, LLC as the beneficial owner. This Form 4 amendment is being filed to report the correct beneficial owner as the Reporting Person. Except as noted in this amended Form 4, all other information disclosed in the Reporting Person's original Form 4 was accurately reported.
F2 The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
F3 The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F4 This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.